½ÃÀ庸°í¼­
»óǰÄÚµå
1678515

¼¼°èÀÇ Àν¶¸° ÆßÇÁ ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м®(À¯Çüº°, Á¦Ç°º°, ºÎ¼Óǰº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°), ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Insulin Pump Market Size, Share & Trends Analysis Report By Type (Patch Pumps, Tethered Pumps), By Product (Mini Med, Accu-Chek), By Accessories, By End-use (Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 220 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Àν¶¸° ÆßÇÁ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è Àν¶¸° ÆßÇÁ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 96¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025³âºÎÅÍ 2030³â¿¡ °ÉÃÄ 8.42% ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ±â¼úÀÇ Áøº¸¿Í ÀüÅëÀûÀÎ ¹æ¹ý¿¡ ´ëÇÑ ÆßÇÁÀÇ Ã¤ÅÃÀÔ´Ï´Ù. ÀÌ ÆßÇÁ´Â ¸ÅÀÏ ¿©·¯ ¹ø Àν¶¸° Áֻ簡 ÇÊ¿äÇÑ »ç¶÷µé¿¡°Ô ¸Å¿ì À¯¿ëÇÕ´Ï´Ù.

Àν¶¸° ÆßÇÁ´Â Àν¶¸°À» ¼öµ¿ ¶Ç´Â ÀÚµ¿À¸·Î Åõ¿©ÇÒ ¼ö ÀÖ´Â ±â°èÀÔ´Ï´Ù. ÀÌ ÆßÇÁ´Â ƯÁ¤ º¹¿ë·®À» Åõ¿©Çϵµ·Ï ÇÁ·Î±×·¡¹Ö ÇÒ ¼ö ÀÖÀ¸¸ç ½ÄÀü°ú °°Àº ÇÊ¿äÇÒ ¶§ ´õ ¸¹Àº ¾çÀÇ Æ÷µµ´çÀ» Åõ¿© ÇÒ ¼ö ÀÖ½À´Ï´Ù. ȯÀÚ´Â ÀÌ·¯ÇÑ ÀåÄ¡¸¦ ½º¸¶Æ®Æù¿¡ ¿¬°áÇϰí Ç÷´ç ÃøÁ¤Ä¡¸¦ ±³Á¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¼ú Áøº¸¿Í ½ÅÁ¦Ç° Ãâ½Ãµµ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» Ȱ¼ºÈ­Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, MedtronicÀÇ MiniMed 670G ½Ã½ºÅÛÀº Àΰø ÃéÀå ¿ªÇÒÀ» ÇÏ´Â ¼¼°è ÃÖÃÊÀÇ ÇÏÀ̺긮µå Æó¼â ·çÇÁ ½Ã½ºÅÛÀÔ´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ȯÀÚÀÇ CGM ÃøÁ¤Ä¡¿¡ µû¶ó ÀÚµ¿ Àν¶¸° Åõ¿©¸¦ ¼öÇàÇÕ´Ï´Ù.

Àν¶¸° ÆßÇÁ ½ÃÀåÀº Á¤ºÎ ¹× ±¹Á¦ ´ç´¢º´ ¿¬ÇÕ(IDF)°ú °°Àº °Ç°­ °ü¸® Á¶Á÷¿¡ ÀÇÇÑ ´ç´¢º´ °ü¸®¸¦ À§ÇÑ Áö¼ÓÀûÀÎ ³ë·ÂÀ¸·Î ¿¹Ãø ±â°£ µ¿¾È ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ´Üü´Â ÇÊ¿äÇÑ Àü¹® Áö½ÄÀ» Á¦°øÇϰí ÀÌÇØ °ü°èÀÚ ¹× ÆÄÆ®³Ê ³×Æ®¿öÅ©¸¦ ÅëÇØ ´ç´¢º´ °è¹ß Ä·ÆäÀÎÀ» Áö¿øÇÕ´Ï´Ù. ¶ÇÇÑ ÀÇ·áºñ Áõ°¡µµ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °Ô´Ù°¡ ÀÌ ½ÃÀåÀº ÄÄÆÑÆ®ÇÑ »çÀÌÁî¿Í »ç¿ë ¿ëÀ̼ºÀ» ¿øµ¿·ÂÀ¸·Î ±âÁ¸ÀÇ ²öÀÌ ´Þ¸° ÆßÇÁ¿¡¼­ ÆÐÄ¡ ÆßÇÁ·ÎÀÇ ÀÌÇàÀÌ ÁøÇàµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àν¶¸° ÆßÇÁ ½ÃÀå : ºÐ¼® °³¿ä

  • Å×´õÇü ÆßÇÁ ºÐ¾ß°¡ 2024³â ½ÃÀåÀ» µ¶Á¡ÇÏ°í ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ½ÃÀåÀ» ¼±µµÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Å×´õÇü Àν¶¸° ÆßÇÁ´Â ij´¼¶ó¿¡ ¿¬°áµÈ ¾ãÀº Æ©ºê¸¦ ÅëÇØ ½Åü¿¡ ¿¬°áµË´Ï´Ù.
  • MiniMed ºÎ¹®Àº 2024³â¿¡ 52.9%ÀÇ Á¡À¯À²À» Â÷ÁöÇÏ°í ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
  • Àν¶¸° ¼¼Æ® »ðÀÔ ÀåÄ¡ ºÎ¹®Àº 2024³â 41.4%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. Àν¶¸° ¼¼Æ® »ðÀԱ⠽ÃÀåÀÇ ³ôÀº Á¡À¯À²Àº »ç¿ëÀÚ Ä£È­ÀûÀÎ µðÀÚÀΰú Æí¾ÈÇÔÀÇ Çâ»óÀ¸·Î ÇöÀúÇÑ ¼ºÀåÀ¸·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù.
  • º´¿ø ºÎ¹®Àº 2024³â 44.4% ÀÌ»óÀÇ Á¡À¯À²·Î ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. º´¿ø¿¡¼­´Â ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϱâ À§ÇØ Àν¶¸° ÆßÇÁ¸¦ Æ÷ÇÔÇÑ °í±Þ ´ç´¢º´ °ü¸® ±â¼úÀÇ µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Àν¶¸° ÆßÇÁ ½ÃÀå : º¯µ¿ ¿äÀÎ ¹× °æÇâ ¹× ¹üÀ§

  • ½ÃÀå ¿¬°ü Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã, ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • Àν¶¸° ÆßÇÁ ½ÃÀå : ºÐ¼® µµ±¸
    • ¾÷°è ºÐ¼® : Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå Àν¶¸° ÆßÇÁ ½ÃÀå : µð¹ÙÀ̽ºº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ Àν¶¸° ÆßÇÁ ½ÃÀå, º¯µ¿ ºÐ¼® : µð¹ÙÀ̽ºº°
  • ¼¼°èÀÇ Àν¶¸° ÆßÇÁ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м® : µð¹ÙÀ̽ºº°(2018-2030³â)
  • ÆÐÄ¡Çü ÆßÇÁ
  • Å×´õÇü ÆßÇÁ

Á¦5Àå Àν¶¸° ÆßÇÁ ½ÃÀå : Á¦Ç°º° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ Àν¶¸° ÆßÇÁ ½ÃÀå, º¯µ¿ ºÐ¼® : Á¦Ç°º°
  • ¼¼°èÀÇ Àν¶¸° ÆßÇÁ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м® : Á¦Ç°º°(2018-2030³â)
  • MiniMed
  • Accu-Chek
  • Tandem
  • Omnipod
  • My life omnipod
  • ±âŸ
    • ±âŸ

Á¦6Àå Àν¶¸° ÆßÇÁ ½ÃÀå : ºÎ¼Óǰº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ Àν¶¸° ÆßÇÁ ½ÃÀå, º¯µ¿ ºÐ¼® : ºÎ¼Óǰº°
  • ¼¼°èÀÇ Àν¶¸° ÆßÇÁ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м® : ºÎ¼Óǰº°(2018-2030³â)
  • Àν¶¸° ÀúÀå¼Ò, īƮ¸®Áö
  • Àν¶¸° ¼¼Æ® »ðÀÔ ÀåÄ¡
  • ¹èÅ͸®

Á¦7Àå Àν¶¸° ÆßÇÁ ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ Àν¶¸° ÆßÇÁ ½ÃÀå, º¯µ¿ ºÐ¼® : ÃÖÁ¾ ¿ëµµº°
  • ¼¼°èÀÇ Àν¶¸° ÆßÇÁ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м® : ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
  • º´¿ø ¹× Ŭ¸®´Ð
  • ÀçÅÃÄ¡·á
  • ¿¬±¸¼Ò

Á¦8Àå Àν¶¸° ÆßÇÁ ½ÃÀå :Áö¿ªº° ÃßÁ¤, µ¿Çâ, ºÐ¼®(À¯Çüº°, Á¦Ç°º°, ºÎ¼Óǰº°, ÃÖÁ¾ ¿ëµµº°)

  • ½ÃÀå Á¡À¯À² ºÐ¼® : Áö¿ªº°(2024 ¹× 2030³â)
  • ½ÃÀå ´ë½Ãº¸µå : Áö¿ªº°
  • ¼¼°è ½ÃÀå ÇöȲ : Áö¿ªº°
  • ½ÃÀå ±Ô¸ð ¿¹Ãø°ú µ¿Ç⠺м®(2018-2030³â)
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • ½º¿þµ§
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï ±¸µµ

  • ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м® : ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷º°
  • ±â¾÷, °æÀïÀÇ ºÐ·ù
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
  • ±â¾÷ Æ÷Áö¼Ç ºÐ¼®
  • ±â¾÷ºÐ·ù(½ÅÈï±â¾÷, À̳뺣ÀÌÅÍ, ¸®´õ)
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Medtronic
    • Hoffmann-La Roche AG
    • Tandem Diabetes Care, Inc.
    • Insulet Corporation
    • Ypsomed
    • Sooil development
    • Jiangsu Delfu Co., Ltd.
    • Cellnovo Ltd
    • Valeritas, Inc
SHW 25.04.07

Insulin Pump Market Growth & Trends:

The global insulin pump market size is estimated to reach USD 9.66 billion by 2030, registering to grow at a CAGR of 8.42% from 2025 to 2030 according to a new report by Grand View Research, Inc. The key factors driving the growth of the market are the technological advancements and the adoption of pumps over traditional methods. These pumps are very convenient for people who require daily multiple injections of insulin.

Insulin pump is a machine that enables insulin to be delivered either manually or automatically. These pumps can be programmed to deliver a specific set of doses and can also deliver a larger set of doses of glucose whenever required, such as before a meal. Patients can connect these devices to their smartphones to calibrate blood glucose readings. Technological advancement and new product launches across the globe are also fueling the market during the forecast period. For instance, Medtronic's MiniMed 670G system is the world's first hybrid closed loop system that acts as an artificial pancreas. The system provides automated insulin delivery as per the patient's CGM readings.

The insulin pumps market is anticipated to witness a high growth rate during the forecast period due to the continuous efforts for diabetes control by government and healthcare organizations such as the International Diabetes Federation (IDF). These organizations provide required expertise and support diabetes awareness campaigns through a network of stakeholders and partners. Also, increasing health care funding is anticipated to propel growth. Additionally, the market is expected to witness a shift from the usage of traditional tethered pumps to patch pumps driven by their compact size and ease of use.

Insulin Pump Market Report Highlights:

  • The tethered pumps segment dominated the market in 2024 and expected to lead during the forecast period. Tethered insulin pumps are connected to the body via a small tube linked to a cannula.
  • The MiniMed segment dominated the market with a share of 52.9% in 2024. the high adoption rate and technological advancement.
  • The insulin set insertion devices segment dominated the market with a share of 41.4% in 2024. The insulin set insertion market high share is attributed to notable growth due to advancements in user-friendly designs and enhanced comfort.
  • The hospital segment dominated the market with a share of over 44.4 % in 2024. Hospitals are increasingly adopting advanced diabetes management technologies, including insulin pumps, to improve patient outcomes.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. Accessories
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Outlook
    • 2.2.2. Product Outlook
    • 2.2.3. Accessories Outlook
    • 2.2.4. End Use Outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Insulin Pumps Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High prevalence of diabetes and associated disorders
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Increasing adoption of insulin pumps
      • 3.2.1.4. Increase in number of product approvals
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High-cost barrier
      • 3.2.2.2. Stringent regulatory approvals
  • 3.3. Insulin Pumps Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Insulin Pumps Market: Device Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Insulin Pumps Device Market Movement Analysis
  • 4.3. Global Insulin Pumps Market Size & Trend Analysis, by Device, 2018 to 2030 (USD Million)
  • 4.4. Patch pumps
    • 4.4.1. Patch pumps market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Tethered pumps
    • 4.5.1. Tethered pumps market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Insulin Pumps Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Insulin Pumps Accessories Market Movement Analysis
  • 5.3. Global Insulin Pumps Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. MiniMed
    • 5.4.1. MiniMed market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Accu-Chek
    • 5.5.1. Accu-Chek market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Tandem
    • 5.6.1. Tandem market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Omnipod
    • 5.7.1. Omnipod market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. My life omnipod
    • 5.8.1. My life omnipod market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others
    • 5.9.2. market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Insulin Pumps Market: Accessories Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Insulin Pumps Accessories Market Movement Analysis
  • 6.3. Global Insulin Pumps Market Size & Trend Analysis, by Accessories, 2018 to 2030 (USD Million)
  • 6.4. Insulin reservoir or cartridges
    • 6.4.1. Insulin reservoir or cartridges market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Insulin set insertion devices
    • 6.5.1. Insulin set insertion devices market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Battery
    • 6.6.1. Battery market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Insulin Pumps Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Insulin Pumps End Use Market Movement Analysis
  • 7.3. Global Insulin Pumps Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals & Clinics
    • 7.4.1. Hospitals & Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Homecare
    • 7.5.1. Homecare market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Laboratories
    • 7.6.1. Laboratories market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Insulin Pumps Market: Regional Estimates & Trend Analysis By Type, Product, Accessories, End Use

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Competitive scenario
      • 8.5.1.3. Regulatory framework
      • 8.5.1.4. Reimbursement structure
      • 8.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Regulatory framework
      • 8.5.2.4. Reimbursement structure
      • 8.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Competitive scenario
      • 8.6.1.3. Regulatory framework
      • 8.6.1.4. Reimbursement structure
      • 8.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Regulatory framework
      • 8.6.2.4. Reimbursement structure
      • 8.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. Regulatory framework
      • 8.6.3.4. Reimbursement structure
      • 8.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Competitive scenario
      • 8.6.4.3. Regulatory framework
      • 8.6.4.4. Reimbursement structure
      • 8.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Competitive scenario
      • 8.6.5.3. Regulatory framework
      • 8.6.5.4. Reimbursement structure
      • 8.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Competitive scenario
      • 8.6.6.3. Regulatory framework
      • 8.6.6.4. Reimbursement structure
      • 8.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Competitive scenario
      • 8.6.7.3. Regulatory framework
      • 8.6.7.4. Reimbursement structure
      • 8.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Competitive scenario
      • 8.6.8.3. Regulatory framework
      • 8.6.8.4. Reimbursement structure
      • 8.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Competitive scenario
      • 8.7.1.3. Regulatory framework
      • 8.7.1.4. Reimbursement structure
      • 8.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Regulatory framework
      • 8.7.2.4. Reimbursement structure
      • 8.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Regulatory framework
      • 8.7.3.4. Reimbursement structure
      • 8.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Competitive scenario
      • 8.7.4.3. Regulatory framework
      • 8.7.4.4. Reimbursement structure
      • 8.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Competitive scenario
      • 8.7.5.3. Regulatory framework
      • 8.7.5.4. Reimbursement structure
      • 8.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Competitive scenario
      • 8.7.6.3. Regulatory framework
      • 8.7.6.4. Reimbursement structure
      • 8.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Competitive scenario
      • 8.8.1.3. Regulatory framework
      • 8.8.1.4. Reimbursement structure
      • 8.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Competitive scenario
      • 8.8.2.3. Regulatory framework
      • 8.8.2.4. Reimbursement structure
      • 8.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Mexico
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Competitive scenario
      • 8.8.3.3. Regulatory framework
      • 8.8.3.4. Reimbursement structure
      • 8.8.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Competitive scenario
      • 8.9.1.3. Regulatory framework
      • 8.9.1.4. Reimbursement structure
      • 8.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Competitive scenario
      • 8.9.2.3. Regulatory framework
      • 8.9.2.4. Reimbursement structure
      • 8.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Competitive scenario
      • 8.9.3.3. Regulatory framework
      • 8.9.3.4. Reimbursement structure
      • 8.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Competitive scenario
      • 8.9.4.3. Regulatory framework
      • 8.9.4.4. Reimbursement structure
      • 8.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Key company market share analysis, 2024
  • 9.4. Company Position Analysis
  • 9.5. Company Categorization (Emerging Players, Innovators and Leaders
  • 9.6. Company Profiles
    • 9.6.1. Medtronic
      • 9.6.1.1. Company overview
      • 9.6.1.2. Financial performance
      • 9.6.1.3. Device benchmarking
      • 9.6.1.4. Strategic initiatives
    • 9.6.2. Hoffmann-La Roche AG
      • 9.6.2.1. Company overview
      • 9.6.2.2. Financial performance
      • 9.6.2.3. Device benchmarking
      • 9.6.2.4. Strategic initiatives
    • 9.6.3. Tandem Diabetes Care, Inc.
      • 9.6.3.1. Company overview
      • 9.6.3.2. Financial performance
      • 9.6.3.3. Device benchmarking
      • 9.6.3.4. Strategic initiatives
    • 9.6.4. Insulet Corporation
      • 9.6.4.1. Company overview
      • 9.6.4.2. Financial performance
      • 9.6.4.3. Device benchmarking
      • 9.6.4.4. Strategic initiatives
    • 9.6.5. Ypsomed
      • 9.6.5.1. Company overview
      • 9.6.5.2. Financial performance
      • 9.6.5.3. Device benchmarking
      • 9.6.5.4. Strategic initiatives
    • 9.6.6. Sooil development
      • 9.6.6.1. Company overview
      • 9.6.6.2. Financial performance
      • 9.6.6.3. Device benchmarking
      • 9.6.6.4. Strategic initiatives
    • 9.6.7. Jiangsu Delfu Co., Ltd.
      • 9.6.7.1. Company overview
      • 9.6.7.2. Financial performance
      • 9.6.7.3. Device benchmarking
      • 9.6.7.4. Strategic initiatives
    • 9.6.8. Cellnovo Ltd
      • 9.6.8.1. Company overview
      • 9.6.8.2. Financial performance
      • 9.6.8.3. Device benchmarking
      • 9.6.8.4. Strategic initiatives
    • 9.6.9. Valeritas, Inc
      • 9.6.9.1. Company overview
      • 9.6.9.2. Financial performance
      • 9.6.9.3. Device benchmarking
      • 9.6.9.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦